Noah Wald-Dickler1, Paul D Holtom2, Matthew C Phillips3, Robert M Centor4, Rachael A Lee4, Rachel Baden3, Brad Spellberg5. 1. Los Angeles County + University of Southern California Medical Center, Los Angeles; Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles; Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles. 2. Los Angeles County + University of Southern California Medical Center, Los Angeles; Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles. 3. Los Angeles County + University of Southern California Medical Center, Los Angeles. 4. Department of Medicine, University of Alabama at Birmingham School of Medicine, Birmingham; Birmingham Veterans Affairs (VA) Medical Center, Birmingham, Ala. 5. Los Angeles County + University of Southern California Medical Center, Los Angeles. Electronic address: bspellberg@dhs.lacounty.gov.
Abstract
BACKGROUND: We sought to determine if controlled, prospective clinical data validate the long-standing belief that intravenous (IV) antibiotic therapy is required for the full duration of treatment for 3 invasive bacterial infections: osteomyelitis, bacteremia, and infective endocarditis. METHODS: We performed a systematic review of published, prospective, controlled trials that compared IV-only to oral stepdown regimens in the treatment of these diseases. Using the PubMed database, we identified 7 relevant randomized controlled trials (RCTs) of osteomyelitis, 9 of bacteremia, 1 including both osteomyelitis and bacteremia, and 3 of endocarditis, as well as one quasi-experimental endocarditis study. Study results were synthesized via forest plots and funnel charts (for risk of study bias), using RevMan 5.4.1 and Meta-Essentials freeware, respectively. RESULTS: The 21 studies demonstrated either no difference in clinical efficacy, or superiority of oral versus IV-only antimicrobial therapy, including for mortality; in no study was IV-only treatment superior in efficacy. The frequency of catheter-related adverse events and duration of inpatient hospitalization were both greater in IV-only groups. DISCUSSION: Numerous prospective, controlled investigations demonstrate that oral antibiotics are at least as effective, safer, and lead to shorter hospitalizations than IV-only therapy; no contrary data were identified. Treatment guidelines should be modified to indicate that oral therapy is appropriate for reasonably selected patients with osteomyelitis, bacteremia, and endocarditis.
BACKGROUND: We sought to determine if controlled, prospective clinical data validate the long-standing belief that intravenous (IV) antibiotic therapy is required for the full duration of treatment for 3 invasive bacterial infections: osteomyelitis, bacteremia, and infective endocarditis. METHODS: We performed a systematic review of published, prospective, controlled trials that compared IV-only to oral stepdown regimens in the treatment of these diseases. Using the PubMed database, we identified 7 relevant randomized controlled trials (RCTs) of osteomyelitis, 9 of bacteremia, 1 including both osteomyelitis and bacteremia, and 3 of endocarditis, as well as one quasi-experimental endocarditis study. Study results were synthesized via forest plots and funnel charts (for risk of study bias), using RevMan 5.4.1 and Meta-Essentials freeware, respectively. RESULTS: The 21 studies demonstrated either no difference in clinical efficacy, or superiority of oral versus IV-only antimicrobial therapy, including for mortality; in no study was IV-only treatment superior in efficacy. The frequency of catheter-related adverse events and duration of inpatient hospitalization were both greater in IV-only groups. DISCUSSION: Numerous prospective, controlled investigations demonstrate that oral antibiotics are at least as effective, safer, and lead to shorter hospitalizations than IV-only therapy; no contrary data were identified. Treatment guidelines should be modified to indicate that oral therapy is appropriate for reasonably selected patients with osteomyelitis, bacteremia, and endocarditis.
Authors: Henning Bundgaard; Nikolaj Ihlemann; Sabine U Gill; Niels E Bruun; Hanne Elming; Trine Madsen; Kaare T Jensen; Kurt Fursted; Jens J Christensen; Martin Schultz; Lauge Østergaard; Flemming Rosenvinge; Henrik C Schønheyder; Jannik Helweg-Larsen; Emil L Fosbøll; Lars Køber; Christian Torp-Pedersen; Niels Tønder; Claus Moser; Kasper Iversen Journal: N Engl J Med Date: 2019-03-17 Impact factor: 91.245
Authors: Sheldon L Kaplan; Jaime G Deville; Ram Yogev; Ma Rayo Morfin; Elba Wu; Stuart Adler; Barbara Edge-Padbury; Sharon Naberhuis-Stehouwer; Jon B Bruss Journal: Pediatr Infect Dis J Date: 2003-08 Impact factor: 2.129
Authors: Yoelkys Morales; Emma Smyth; Julia Zubiago; Benjamin Bearnot; Alysse G Wurcel Journal: Open Forum Infect Dis Date: 2022-10-19 Impact factor: 4.423
Authors: Brad Spellberg; Gloria Aggrey; Meghan B Brennan; Brent Footer; Graeme Forrest; Fergus Hamilton; Emi Minejima; Jessica Moore; Jaimo Ahn; Michael Angarone; Robert M Centor; Kartikeya Cherabuddi; Jennifer Curran; Kusha Davar; Joshua Davis; Mei Qin Dong; Bassam Ghanem; Doug Hutcheon; Philipp Jent; Minji Kang; Rachael Lee; Emily G McDonald; Andrew M Morris; Rebecca Reece; Ilan S Schwartz; Miranda So; Steven Tong; Christopher Tucker; Noah Wald-Dickler; Erica J Weinstein; Riley Williams; Christina Yen; Shiwei Zhou; Todd C Lee Journal: JAMA Netw Open Date: 2022-05-02
Authors: Nichole Moore; Michael Kohut; Henry Stoddard; Debra Burris; Frank Chessa; Monica K Sikka; Daniel Solomon; Colleen M Kershaw; Ellen Eaton; Rebecca Hutchinson; Kathleen M Fairfield; Thomas J Stopka; Peter Friedmann; Kinna Thakarar Journal: Ther Adv Infect Dis Date: 2022-10-06